June 11, 2025 11:32 AM EDTUpdated June 12, 03:08 PM
Editor's note
R&D
AI

Watch Post-Hoc Live: What hap­pens when AI thinks in ways we can’t un­der­stand?

Drew Armstrong

Executive Editor

We’re back for the sec­ond time this week! To­day on Post-Hoc Live, we were joined by some­body I’ve want­ed to have on for a long …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

As­traZeneca inks AI drug R&D deal with Chi­nese phar­ma for $110M up­front 

Bris­tol My­ers gets a key strate­gist with 'Team Shib­s'; Idor­sia to change CEOs af­ter it 'hit a re­set but­ton'

Rein Ther­a­peu­tics study on clin­i­cal hold; Beam up­dates sick­le cell ther­a­py da­ta

With HIV pre­ven­tion un­der at­tack, how might Gilead’s new PrEP in­jec­tion fare?

An­oth­er round of con­sol­i­da­tion is com­ing, FDA com­mis­sion­er tells staff

sponsored

McKesson leads the charge in rev­o­lu­tion­iz­ing pre­ci­sion on­col­o­gy in com­mu­ni­ty prac­tices

A service from the Financial Times